Cite
HARVARD Citation
Lu, M. et al. (2022). Optimal duration of adjuvant bisphosphonate treatment for high‐risk early breast cancer: Results from a SUCCESS trial. Thoracic cancer. 13 (3), pp. 519-520. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Lu, M. et al. (2022). Optimal duration of adjuvant bisphosphonate treatment for high‐risk early breast cancer: Results from a SUCCESS trial. Thoracic cancer. 13 (3), pp. 519-520. [Online].